Your legacy can help bring an end to CMT. Learn how a planned gift can make an impact for generations to come.
CMTA Invests $423K to Accelerate CMT Diagnostics and Gene Discovery
…will help researchers pinpoint additional CMT-causing genes, paving the way for new treatment possibilities. “This CMTA-STAR initiative builds on our existing partnership with GENESIS, which has already led to the…
Alliance Partner NMD Pharma A/S Launches Phase II SYNAPSE-CMT Trial with First Patient Dosed at CMTA Center of Excellence
…tolerability, and efficacy (how well the treatment works) of NMD670 over 21 days in 80 adult patients with genetically confirmed CMT types 1 and 2. Shared Vision for Progress “This…
CMT2S Breakthrough
…marks a significant step forward for community members who have CMT2S. CMT2S is a very rare and often debilitating autosomal recessive type of CMT. A potential treatment for CMT2S, Vanda’s…
The CMTA Mourns the Loss of Scientific Advisory Board Member and Esteemed CMT Clinical Researcher
…Laura Feltri will be deeply missed.” Dr. Feltri was a dedicated supporter of our mission to support the development of new treatments for CMT, to improve the quality of life…
CMTA Awards Over Half a Million Dollars to Fuel Research in Demyelinating Forms of CMT
…global leadership in advancing treatments for CMT and it underscores the association’s commitment to improving the lives of those who have CMT, while strengthening its dedication to developing treatments and,…
CMTA Updates List of Neurotoxic Meds Potentially More Hazardous to CMT Patients
…than for people who do not have CMT. The reviewers emphasized the importance of not denying patients with CMT treatments that may prolong life expectancy for cancer or improve their…
CMTA Lunch & Learn: Neuro-Toxic Medication List Update
07/13/2023 @ 12:00 pm – 1:00 pm – Please join us on July 13 at 12:00 p.m. Eastern Time to hear an update on the newly reviewed and revised CMT Neuro-toxic Medication List. The CMTA funded a grant awarded to Guido Cavaletti, MD at the University of Milano-Bicocca to review and update the current CMT neuro-toxic medication list. Dr. Cavaletti and colleague, Dr. […]
CMTA Invests $210K in Long-Read Sequencing to Accelerate CMT Gene Discovery
…don’t have a genetic diagnosis,” said Dr. Cortese. “With CMTA’s support, we hope to close this diagnostic gap and open the door to future research participation and potential treatment opportunities…
SORD Research
…some of the advances in the eventual treatment of axon degeneration may be applicable as these therapies are developed. If your type is not yet identified, please visit a CMTA…